Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index

Seminars in Arthritis and Rheumatism

Volumn 48, Issue 1, 2018, Pages 77-82

  Berti, Alvise ^a,b   Cornec, Divi ^b,c   Medina Inojosa, Jose R ^d   Matteson, Eric L ^b   Murad, M Hassan ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Mayo Clinic   (United States)

^c Universite de Brest   (France)

^d MAYO CLINIC   (United States)

Author keywords

Fragility index; Giant cell arteritis; Meta analysis; Randomized control trials; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; PLACEBO; TOCILIZUMAB; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

CLINICAL STUDY; FRAGILITY INDEX; GIANT CELL ARTERITIS; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RELIABILITY; REVIEW; RISK ASSESSMENT; STATISTICAL PARAMETERS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; TREATMENT OUTCOME;

EID: 85042510457     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2017.12.009     Document Type: Review

References (32)

1. Crowson, C.S., Matteson, E.L., Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Semin Arthritis Rheum, 2017.
2. Weyand, C.M., Goronzy, J.J., Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med, 371, 2014, 1653.
3. Berti, A., Campochiaro, C., Cavalli, G., Pepe, G., Praderio, L., Sabbadini, M.G., et al. Giant cell arteritis restricted to the limb arteries: an overlooked clinical entity. Autoimmun Rev 14 (2015), 352–357.
4. Andersson, R., Malmvall, B.E., Bengtsson, B.A., Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 220 (1986), 465–469.
5. Proven, A., Gabriel, S.E., Orces, C., O'Fallon, W.M., Hunder, G.G., Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49 (2003), 703–708.
6. Buttgereit, F., Dejaco, C., Matteson, E.L., Dasgupta, B., Polymyalgia rheumatica and giant cell arteritis: a systematic review. J Am Med Assoc. 315 (2016), 2442–2458.
7. Nesher, G., Sonnenblick, M., Friedlander, Y., Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 21 (1994), 1283–1286.
8. Delecoeuillerie, G., Joly, P., Cohen de Lara, A., Paolaggi, J.B., Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 47 (1988), 733–739.
9. Villiger, P.M., Adler, S., Kuchen, S., Wermelinger, F., Dan, D., Fiege, V., et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 387 (2016), 1921–1927.
10. Stone, J.H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377 (2017), 317–328.
11. Langford, C.A., Cuthbertson, D., Ytterberg, S.R., Khalidi, N., Monach, P.A., Carette, S., et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol (Hoboken, NJ). 69 (2017), 837–845.
12. Seror, R., Baron, G., Hachulla, E., Debandt, M., Larroche, C., Puechal, X., et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 73 (2014), 2074–2081.
13. Hoffman, G.S., Cid, M.C., Rendt-Zagar, K.E., Merkel, P.A., Weyand, C.M., Stone, J.H., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146 (2007), 621–630.
14. Martinez-Taboada, V.M., Rodriguez-Valverde, V., Carreno, L., Lopez-Longo, J., Figueroa, M., Belzunegui, J., et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67 (2008), 625–630.
15. Spiera, R.F., Mitnick, H.J., Kupersmith, M., Richmond, M., Spiera, H., Peterson, M.G., et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19 (2001), 495–501.
16. Hoffman, G.S., Cid, M.C., Hellmann, D.B., Guillevin, L., Stone, J.H., Schousboe, J., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46 (2002), 1309–1318.
17. Jover, J.A., Hernandez-Garcia, C., Morado, I.C., Vargas, E., Banares, A., Fernandez-Gutierrez, B., Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 134 (2001), 106–114.
18. Mazlumzadeh, M., Hunder, G.G., Easley, K.A., Calamia, K.T., Matteson, E.L., Griffing, W.L., et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 54 (2006), 3310–3318.
19. Chevalet, P., Barrier, J.H., Pottier, P., Magadur-Joly, G., Pottier, M.A., Hamidou, M., et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 27 (2000), 1484–1491.
20. De Silva, M., Hazleman, B.L., Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45 (1986), 136–138.
21. Walsh, M., Srinathan, S.K., McAuley, D.F., Mrkobrada, M., Levine, O., Ribic, C., et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol 67 (2014), 622–628.
22. Goodman, S.N., Toward evidence-based medical statistics. 1: the P value fallacy. Ann Intern Med 130 (1999), 995–1004.
23. Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J (Clin Res ed) 336 (2008), 924–926.
24. Guyatt, G.H., Oxman, A.D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol 64 (2011), 1283–1293.
25. Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis, J.P.A., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6, 2009.
26. Mahr, A.D., Jover, J.A., Spiera, R.F., Hernandez-Garcia, C., Fernandez-Gutierrez, B., Lavalley, M.P., et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56 (2007), 2789–2797.
27. Khan, M., Evaniew, N., Gichuru, M., Habib, A., Ayeni, O.R., Bedi, A., et al. The fragility of statistically significant findings from randomized trials in sports surgery: a systematic survey. Am J Sports Med 45 (2017), 2164–2170.
28. Chavalarias, D., Wallach, J.D., Li, A.H., Ioannidis, J.P., Evolution of reporting p values in the biomedical literature, 1990–2015. J Am Med Assoc 315 (2016), 1141–1148.
29. Ridgeon, E.E., Young, P.J., Bellomo, R., Mucchetti, M., Lembo, R., Landoni, G., The fragility index in multicenter randomized controlled critical care trials. Crit Care Med 44 (2016), 1278–1284.
30. Matics, T.J., Khan, N., Jani, P., Kane, J.M., The fragility index in a cohort of pediatric randomized controlled trials. J Clin Med, 6, 2017.
31. Docherty, K.F., Campbell, R.T., Jhund, P.S., Petrie, M.C., McMurray, J.J.V., How robust are clinical trials in heart failure?. Eur Heart J 38 (2017), 338–345.
32. Evaniew, N., Files, C., Smith, C., Bhandari, M., Ghert, M., Walsh, M., et al. The fragility of statistically significant findings from randomized trials in spine surgery: a systematic survey. Spine J 15 (2015), 2188–2197.